BiotechTube
Kano Therapeutics

Kano Therapeutics

San Diego, United States· Est.
kanotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Kano Therapeutics is a private, pre-clinical stage biotech founded in 2020 and based in San Diego, CA. The company has developed a proprietary platform for manufacturing circular single-stranded DNA (cssDNA), which it positions as a superior genetic payload for next-generation cell and gene therapies. Kano operates as a platform and product company, licensing its cssDNA technology and providing integrated supply to partners, with early validation through collaborations with entities like Merck KGaA. The company is pre-revenue and appears to be funded by grants and partnerships as it advances its manufacturing and platform development.

Drug Delivery

Technology Platform

Circular single-stranded DNA (cssDNA) manufacturing and engineering platform for use as a genetic payload in cell and gene therapies. Focus on precision editing, superior persistence, and in vivo safety via fermentation-based production.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The platform addresses a fundamental bottleneck in the rapidly growing cell and gene therapy market by providing a safer, more scalable DNA payload.
Partnership-driven model allows Kano to leverage the R&D pipelines of multiple therapeutic developers without bearing full drug development risk.
Grant funding and strategic collaborations provide non-dilutive capital and validation.

Risk Factors

Unproven long-term safety and efficacy of the novel cssDNA platform in human trials.
Commercial success is entirely dependent on adoption by partners and the success of their therapeutic programs.
Significant competition from established viral vectors and other emerging DNA/RNA payload technologies.

Competitive Landscape

Kano competes in the genetic medicine payload space against dominant viral vector technologies (lentivirus, AAV) and alternative non-viral methods like electroporation of double-stranded DNA or mRNA. Competitors include other companies innovating in DNA template design, synthetic biology, and novel delivery modalities. Its key differentiators are the cssDNA structure and scalable fermentation manufacturing.

More companies in United States →